# Tumor Immunology and Immunotherapy (TII)

> **NIH NIH P30** · UNIVERSITY OF MARYLAND BALTIMORE · 2020 · $48,776

## Abstract

18.0 Abstract: Tumor Immunology and Immunotherapy Program 
The overarching goal of the Tumor Immunology and Immunotherapy (TII) Program of UMGCC is to develop 
and implement immune-based strategies to prevent, treat, and/or monitor malignant diseases and disease 
progression. To achieve this goal, the program focuses on three specific aims: Theme 1: Cell-based cancer 
immunotherapies—elicit active tumor immunity capable of reducing or preventing malignant cell growth; 
Theme 2: Inhibiting immunosuppression—develop strategies to overcome tumor immune evasion; and 
Theme 3: Cancer and inflammation—elucidate the roles for infection and inflammatory responses in cancer 
development. The successful implementation of this work is facilitated by strong interactions between clinicians 
and basic researchers. Program research and mentoring strategies are designed to promote inter- and 
intraprogrammatic interaction and mentoring of junior research and clinical faculty. 
The TII program has 60 members representing 17 academic departments and 5 schools/colleges of the 
University of Maryland. Members of the program conduct cancer-focused research that receives $4.1 million 
total annual funding, including $0.6 million from NCI and $2.6 million from other peer-reviewed sources. In 
addition, TII Program members receive $0.9 million annually from non-peer-reviewed funding sources. 
Between January 2010 and December 2014, TII members authored 366 cancer-related publications, of which 
21 percent resulted from intraprogrammatic and 22 percent from interprogrammatic collaborations. 
Approximately 52 percent of the publications represent collaborations with external investigators. Research 
efforts by TII faculty are supported by extensive use of the FCSS, BSS, and PBSS.

## Key facts

- **NIH application ID:** 9985003
- **Project number:** 5P30CA134274-13
- **Recipient organization:** UNIVERSITY OF MARYLAND BALTIMORE
- **Principal Investigator:** Xuefang Cao
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $48,776
- **Award type:** 5
- **Project period:** 2008-08-08 → 2021-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9985003

## Citation

> US National Institutes of Health, RePORTER application 9985003, Tumor Immunology and Immunotherapy (TII) (5P30CA134274-13). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9985003. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*